Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
1.
Proc Natl Acad Sci U S A ; 109(43): 17561-6, 2012 Oct 23.
Artículo en Inglés | MEDLINE | ID: mdl-23045683

RESUMEN

The recent approval of a prostate cancer vaccine has renewed hope for anticancer immunotherapies. However, the immunosuppressive tumor microenvironment may limit the effectiveness of current immunotherapies. Antiangiogenic agents have the potential to modulate the tumor microenvironment and improve immunotherapy, but they often are used at high doses in the clinic to prune tumor vessels and paradoxically may compromise various therapies. Here, we demonstrate that targeting tumor vasculature with lower vascular-normalizing doses, but not high antivascular/antiangiogenic doses, of an anti-VEGF receptor 2 (VEGFR2) antibody results in a more homogeneous distribution of functional tumor vessels. Furthermore, lower doses are superior to the high doses in polarizing tumor-associated macrophages from an immune inhibitory M2-like phenotype toward an immune stimulatory M1-like phenotype and in facilitating CD4(+) and CD8(+) T-cell tumor infiltration. Based on this mechanism, scheduling lower-dose anti-VEGFR2 therapy with T-cell activation induced by a whole cancer cell vaccine therapy enhanced anticancer efficacy in a CD8(+) T-cell-dependent manner in both immune-tolerant and immunogenic murine breast cancer models. These findings indicate that vascular-normalizing lower doses of anti-VEGFR2 antibody can reprogram the tumor microenvironment away from immunosuppression toward potentiation of cancer vaccine therapies. Given that the combinations of high doses of bevacizumab with chemotherapy have not improved overall survival of breast cancer patients, our study suggests a strategy to use antiangiogenic agents in breast cancer more effectively with active immunotherapy and potentially other anticancer therapies.


Asunto(s)
Inhibidores de la Angiogénesis/farmacología , Neoplasias de la Mama/irrigación sanguínea , Inmunoterapia , Microambiente Tumoral , Animales , Neoplasias de la Mama/inmunología , Femenino , Humanos , Ratones , Receptor 2 de Factores de Crecimiento Endotelial Vascular/inmunología
2.
J Hematol Oncol ; 7: 15, 2014 Feb 24.
Artículo en Inglés | MEDLINE | ID: mdl-24565018

RESUMEN

BACKGROUND: Although dendritic cell (DC) vaccines are considered to be promising treatments for advanced cancer, their production and administration is costly and labor-intensive. We developed a novel immunotherapeutic agent that links a single-chain antibody variable fragment (scFv) targeting mesothelin (MSLN), which is overexpressed on ovarian cancer and mesothelioma cells, to Mycobacterium tuberculosis (MTB) heat shock protein 70 (Hsp70), which is a potent immune activator that stimulates monocytes and DCs, enhances DC aggregation and maturation and improves cross-priming of T cells mediated by DCs. METHODS: Binding of this fusion protein with MSLN on the surface of tumor cells was measured by flow cytometry and fluorescence microscopy. The therapeutic efficacy of this fusion protein was evaluated in syngeneic and orthotopic mouse models of papillary ovarian cancer and malignant mesothelioma. Mice received 4 intraperitoneal (i.p.) treatments with experimental or control proteins post i.p. injection of tumor cells. Ascites-free and overall survival time was measured. For the investigation of anti-tumor T-cell responses, a time-matched study was performed. Splenocytes were stimulated with peptides, and IFNγ- or Granzyme B- generating CD3+CD8+ T cells were detected by flow cytometry. To examine the role of CD8+ T cells in the antitumor effect, we performed in vivo CD8+ cell depletion. We further determined if the fusion protein increases DC maturation and improves antigen presentation as well as cross-presentation by DCs. RESULTS: We demonstrated in vitro that the scFvMTBHsp70 fusion protein bound to the tumor cells used in this study through the interaction of scFv with MSLN on the surface of these cells, and induced maturation of bone marrow-derived DCs. Use of this bifunctional fusion protein in both mouse models significantly enhanced survival and slowed tumor growth while augmenting tumor-specific CD8+ T-cell dependent immune responses. We also demonstrated in vitro and in vivo that the fusion protein enhanced antigen presentation and cross-presentation by targeting tumor antigens towards DCs. CONCLUSIONS: This new cancer immunotherapy has the potential to be cost-effective and broadly applicable to tumors that overexpress mesothelin.


Asunto(s)
Vacunas contra el Cáncer/farmacología , Proteínas Ligadas a GPI/inmunología , Proteínas HSP70 de Choque Térmico/inmunología , Neoplasias Pulmonares/terapia , Mesotelioma/terapia , Neoplasias Ováricas/terapia , Animales , Vacunas contra el Cáncer/inmunología , Células Dendríticas/inmunología , Modelos Animales de Enfermedad , Supervivencia sin Enfermedad , Femenino , Proteínas Ligadas a GPI/farmacología , Proteínas HSP70 de Choque Térmico/genética , Humanos , Neoplasias Pulmonares/inmunología , Mesotelina , Mesotelioma/inmunología , Mesotelioma Maligno , Ratones , Ratones Endogámicos C57BL , Neoplasias Ováricas/inmunología , Proteínas Recombinantes/inmunología , Proteínas Recombinantes/farmacología , Análisis de Supervivencia
3.
PLoS One ; 8(12): e82899, 2013.
Artículo en Inglés | MEDLINE | ID: mdl-24349390

RESUMEN

Safe and effective immunologic adjuvants are often essential for vaccines. However, the choice of adjuvant for licensed vaccines is limited, especially for those that are administered intradermally. We show that non-tissue damaging, near-infrared (NIR) laser light given in short exposures to small areas of skin, without the use of additional chemical or biological agents, significantly increases immune responses to intradermal influenza vaccination without augmenting IgE. The NIR laser-adjuvanted vaccine confers increased protection in a murine influenza lethal challenge model as compared to unadjuvanted vaccine. We show that NIR laser treatment induces the expression of specific chemokines in the skin resulting in recruitment and activation of dendritic cells and is safe to use in both mice and humans. The NIR laser adjuvant technology provides a novel, safe, low-cost, simple-to-use, potentially broadly applicable and clinically feasible approach to enhancing vaccine efficacy as an alternative to chemical and biological adjuvants.


Asunto(s)
Adyuvantes Inmunológicos , Virus de la Influenza A , Vacunas contra la Influenza/inmunología , Rayos Infrarrojos , Rayos Láser , Infecciones por Orthomyxoviridae , Vacunación , Animales , Femenino , Vacunas contra la Influenza/farmacología , Ratones , Infecciones por Orthomyxoviridae/inmunología , Infecciones por Orthomyxoviridae/prevención & control , Piel/inmunología , Vacunación/instrumentación , Vacunación/métodos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA